Seeking Novel Research Programmes to Induce Specific Tregs in vivo

This campaign has been commissioned by an international Japanese pharmaceutical company who combat diseases using a combination of ground‑breaking technology and biology, with an extensive track record of academic collaboration. They are seeking novel research programs which can induce tissue/antigen‑specific regulatory T cells in vivo for immune disorders. 

Specific Points of Interest

• Biology that can induce tissue or antigen specific regulatory T cells in vivo. In addition to Treg cell number, it is preferable to have functional data of induced Tregs (e.g. immune-suppression assay)
• Validation in mouse in vivo data and/or human in vitro data is of highest priority
• Modality: Any platform is within scope, with particular interests in antibodies, nucleic acid, small molecules and proteins/peptides

Diseases of Interest

Immune disorders are within scope for this campaign (for example, Multiple Sclerosis, Type 1 Diabetes, transplantation, Rheumatoid Arthritis, Inflammatory Bowel Disease, Systemic Lupus Erythematosus). 

Out of Scope

• Cell therapy (ex vivo engineering of cell) are not within scope for this campaign
• Symptomatic treatments and treatments affecting entire immune response are not of interest

Developmental Stage

Our client is open to research from basic through to phase 1 clinical trials, however, submissions must contain a target as a minimum.

Incentives for Academics

Submissions will be reviewed on a case by case basis, with potential outcomes including the identification of opportunities for research collaboration or licensing on potential therapeutics.

Submission Information

Submission of 200‑300 word research summary briefs are encouraged, along with any other non‑confidential supporting documents. For example, this could include published papers, weblinks to academic profiles etc.